ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1240

Living with Antiphospholipid Antibodies: A Photovoice Exploration
Abstract Number: 1241

Optimizing Communication of Methotrexate (MTX) Side Effects: A Patient-Centered Approach Focused on Learning Styles and Preferred Language
Abstract Number: 1242

Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms
Abstract Number: 1243

A Patient-Focused Program for Using Steroids Wisely
Abstract Number: 1244

Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO
Abstract Number: 1245

Inpatient Discontinuation of Allopurinol – A Quality Improvement (QI) Initiative
Abstract Number: 1246

Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies
Abstract Number: 1247

Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations
Abstract Number: 1248

Most Prevalent Self-Reported Comorbidities Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis
Abstract Number: 1249

Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Abstract Number: 1250

Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease
Abstract Number: 1251

Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Abstract Number: 1252

Rheuminating About Drugs, Sex, and Alcohol? Assessing the Informational Needs of Adolescents and Young Adults with Rheumatic Disease
Abstract Number: 1253

Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia
Abstract Number: 1254

The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].